Therapeutic Advances in Drug Safety

Papers
(The H4-Index of Therapeutic Advances in Drug Safety is 13. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-06-01 to 2026-06-01.)
ArticleCitations
Development and psychometric assessment of self-reported patient medication safety scale (SR-PMSS)39
Survival outcomes of beta-blocker usage in HER2-positive advanced breast cancer patients: a retrospective cohort study32
Association between number of medications and indicators of potentially inappropriate polypharmacy: a population-based cohort of older adults in Quebec, Canada25
Patient-centered pharmacovigilance: priority actions from the inherited bleeding disorders community22
Adverse drug reactions associated with glycyrrhiza-containing Chinese patent medicines: a literature-based analysis of individual case reports and clinical trials22
Acceptability of a cross-sectoral hospital pharmacist intervention for patients in transition between hospital and general practice: a mixed methods study21
Enhancing pharmacovigilance for robust drug safety monitoring: addressing underreporting and collaborative solutions19
Factors related to dosing frequency and route of administration in methotrexate intolerance among patients with rheumatoid arthritis: a cross-sectional study17
Methotrexate use and risk of abnormal alanine aminotransferase elevation in children with rare inflammatory diseases: a self-controlled case series analysis using a pediatric electronic health record 16
Medication errors by caregivers in the homes of children discharged from a pediatric department in Ghana15
Adverse events of topical ocular prostaglandin medications for glaucoma treatment: a pharmacovigilance study based on the FAERS database14
Semaglutide: a gendered phenomenon—women’s increased vulnerability to adverse drug reactions in the global weight loss trend14
Adverse events associated with statin co-use in breast cancer patients: a disproportionality analysis based on the FDA Adverse Event Reporting System14
0.03852391242981